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Serum Hepcidin and Macrophage Iron Correlate With
MCP-1 Release and Vascular Damage in Patients With
Metabolic Syndrome Alterations
Luca Valenti, Paola Dongiovanni, Benedetta Maria Motta, Dorine W. Swinkels, Paola Bonara,
Raffaela Rametta, Larry Burdick, Cecelia Frugoni, Anna Ludovica Fracanzani, Silvia Fargion
Objective—Increased body iron stores and hepcidin have been hypothesized to promote atherosclerosis by inducing
macrophage iron accumulation and release of cytokines, but direct demonstration in human cells is lacking. The aim of
this study was to evaluate the effect of iron on cytokine release in monocytes ex vivo and the correlation with vascular
damage and to evaluate the relationship among serum levels of hepcidin, cytokines, and vascular damage in patients with
metabolic syndrome alterations.
Methods and Results—Manipulation of iron status with ferric ammonium citrate and hepcidin-25 induced monocyte
chemoattractant protein (MCP)-1 and interleukin-6 in human differentiating monocytes of patients with hyperferritine-
mia associated with the metabolic syndrome (n11), but not in subjects with hemochromatosis or HFE mutations
impairing iron accumulation (n15), and the degree of induction correlated with the presence of carotid plaques,
detected by echocolor–Doppler. In monocytes of healthy subjects (n7), iron and hepcidin increased the mRNA levels
and release of MCP-1, but not of interleukin-6. In 130 patients with metabolic alterations, MCP-1 levels, as detected by
ELISA, were correlated with hepcidin-25 measured by time-of-flight mass spectrometry (P0.005) and were an
independent predictor of the presence of carotid plaques (P0.05).
Conclusion—Hepcidin and macrophage iron correlate with MCP-1 release and vascular damage in high-risk individuals
with metabolic alterations. (Arterioscler Thromb Vasc Biol. 2011;31:683-690.)
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Iron deposition in arterial wall macrophages is increased inatherosclerotic lesions,1,2 and increased iron stores have
been suggested as a marker of cardiovascular risk.3 Several
mechanisms have been proposed to explain the atherogenic
role of iron through oxidative stress catalysis, including
promotion of insulin resistance,4 decreased plasma antioxi-
dant activity, and increased low-density lipoprotein (LDL)
oxidation,5 direct endothelial toxicity,6 enhanced macrophage
activation determining oxidized LDL uptake,7 and acceler-
ated arterial thrombosis.8 Consistently with the previous
findings, iron depletion has been shown to decrease athero-
genesis in experimental models,3,9 blood donation was asso-
ciated with decreased risk for myocardial infarction,10 and
phlebotomy was suggested to decrease the progression of
peripheral vascular disease.11 However, evidence of the
atherogenic effect of iron still controversial.12,13
Hepcidin has recently emerged as the key hormone regu-
lating iron balance.14,15 Hepcidin, whose levels are increased
by iron stores and inflammation, inhibits iron recycling from
macrophages and absorption from enterocytes by binding the
cellular iron exporter ferroportin, thus matching iron avail-
ability to body stores and providing a defense mechanism
against extracellular pathogens during inflammation. In-
creased iron absorption resulting from decreased hepcidin
release, related to common missense mutations of the hered-
itary hemochromatosis (HHC) gene (HFE) or other inherited
defects, is the common pathogenic mechanism of HHC.
Hepcidin may also be induced by subclinical inflammation
and obesity,16 and can determine iron trapping into macro-
phages,17 increasing oxidative stress and transformation into
foam cells in the presence of an atherogenic environment.
Thus, it has been postulated that increased hepcidin may be
responsible for iron-induced atherogenesis and may be in-
volved in the mechanism linking inflammation to vascular
disease.3 This theory would explain the controversial associ-
ation between HFE mutations,18–21 or higher transferrin
saturation,12,13 and susceptibility to vascular disease, which
has so far been considered as a negative proof of the “iron
hypothesis” of atherosclerosis.
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We recently showed that serum ferritin levels, reflecting
iron stores, were an independent predictor of vascular damage
in a population of patients with metabolic alterations defining
the metabolic syndrome (MetS), but only in those negative
for HFE genotypes determining decreased release of hepci-
din.3,7,22,23 In addition, recent data confirmed that individuals
carrying the major C282Y HFE mutation decreasing hepcidin
may be at decreased risk for atherosclerosis, whereas vascular
damage correlated with iron stores in patients predisposed to
iron accumulation.24 Moreover, we reported an association
between hepcidin and carotid vascular damage independently
of other risk factors.22
However, although oxidative stress leading to increased
cytokines release, and especially macrophage chemoattrac-
tant protein (MCP)-1, has been suggested to play a role,25 the
mechanism linking increased macrophage iron content with
accelerated atherogenesis are far from clear, and there is still
no evidence of a modifying effect of HFE genotype on the
atherogenic effect of iron in macrophages.
The aim of this study was to evaluate the following; (1) the
effect of increased intracellular iron content induced by
treatment with iron salts and/or hepcidin on the transcription
and release of atherogenic cytokines in human differentiating
macrophages derived from patients with hyperferritinemia;
(2) the modifying effect of HFE genotype on cellular iron
handling and cytokine release; (3) the correlation between
iron induced cytokine release in vitro and vascular damage,
and finally; and (4) the correlation between serum levels of
hepcidin, proinflammatory mediators, and vascular damage
in patients with metabolic alterations with and without
hyperferritinemia.
Methods
Patients
Experiments in differentiating monocytes were performed on cells
isolated from patients on maintenance phlebotomies for nonalcoholic
fatty liver disease (NAFLD)/metabolic alterations associated with
iron overload,26 related to the presence or not of HFE genotypes
predisposing to iron overload, as defined below (n9 and 11,
respectively), and from subjects with HHC (n6). All patients were
iron-depleted and on maintenance phlebotomies at the time of
evaluation (Table 1). Additional experiments were conducted in
monocytes of male control subjects with HFE wild-type (wt)/wt,
normal iron parameters, and absence of MetS (n7).
Vascular damage, iron status, HFE genotype, hepcidin-25, and
MCP-1 levels were evaluated in 130 consecutive patients with
NAFLD with or without hyperferritinemia attending the outpatient
service of the Metabolic Liver Disease Center in Milan, for whom
serum and DNA samples were available (Table 2).27
HFE Genotype and Hepcidin Levels Determination
The C282Y and H63D HFE mutations were determined by restric-
tion analysis.28 We classified HFE C282Y/H63D, H63D/H63D, and
C282Y/wt as genotypes predisposing to iron overload, whereas HFE
H63D/wt and wt/wt were considered “normal” genotypes on the
Table 1. Clinical Features of Twenty Patients With Nonalcoholic Fatty Liver and MetS
Alterations and of Six With C282Y/ HHC, From Whom Peripheral Blood Monocytes Have
Been Isolated
HFE Status
Normal Iron Overload HHC
No. 11 9 6
Age, yr 509 4812 4911
Sex, F 2 (18) 2 (22) 2 (33)
Ferritin, ng/mL* 808414 (median, 588) 529310 (median, 546) 708281 (median, 580)
Transferrin saturation, %* 3711 3616 8710
Metabolic syndrome 9 (82) 7 (78) 1 (17)
Carotid plaques 7 (64) 2 (22) 1 (17)
*Parameters evaluated at diagnosis; at the time of monocyte collection, all patients were iron depleted and on
maintenance venesections. Except where noted otherwise, values in parentheses are percentages.
Table 2. Clinical Features of One Hundred Thirty Patients With
Nonalcoholic Fatty Liver Disease and MetS Abnormalities With
Complete Characterization of Vascular Damage, Iron Status,
Serum Hepcidin-25, and MCP-1 Levels
Variable Value Range
Age, yr 54.412 28–77
Sex, F 23 (18) . . .
BMI, kg/m2 26.73.5 19.2–39
Smoke, current or previous 28 (21) . . .
Glucose, mmol/L 5.170.9 3.46–10.9
HOMA-R 4.23.3 3.8–32.7
Diabetes 32 (24.2) . . .
Treated hypertension 53 (41) . . .
LDL, mmol/L 3.210.8 0.72–5.33
HDL, mmol/L 1.310.4 0.54–2.46
Triglycerides, mmol/L 1.440.7 0.46–5.1
ALT, IU/mL 38.124 10–163
Transferrin saturation, % 34.011 7–61
Ferritin, ng/mL 399 175–640 10–1366
Hyperferritinemia,
320 mol/L/240 F
188 (37.1) . . .
Hepcidin, nmol/L 2.2 0.95–4.25 0.25–11.7
MCP-1, pg/mL 74.0 64–157 1.5–517
Average, CC-IMT mm 0.880.22 0.4–1.65
Carotid plaques 44 (34) . . .
Values in parentheses are percentages; values in brackets are interquartile
range.
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basis of a previous study in this series of patients.29,30 Patients
homozygous for the C282Y HFE mutation, ie, affected by classic
HHC, were used as positive controls of altered macrophage iron
handling.31
Hepcidin quantification was performed by time-of-flight mass
spectrometry as described recently32 and in serum samples stored at
80°C before evaluation.22 MCP-1 quantification was performed in
serum samples and cell supernatants by the CCL2/MCP-1 ELISA kit
(R&D Systems, Minneapolis, MN).
Isolation of Monocytes and Gene
Expression Analysis
Mononuclear cells were separated using the Lymphoprep method
from peripheral blood33 and treated as described previously.34
Twenty-four hours after plating, the supernatant was removed
leaving differentiating macrophages attached, and new supplemented
medium was added in the presence or not of 150 mol/L ferric
ammonium citrate (FAC), hepcidin-25 0.5 or 3 mol/L (H-5926;
Bachem, Wheil am Rhein, Germany), H2O2 10 mol/L, unless
otherwise specified. Cell purity, as confirmed by flow cytometry
(with anti-CD14 antibodies), was 95% in each case. After further
24 hours cells were harvested and total RNA extracted by the
phenol-chloroform method. First-strand cDNA was synthesized with
equal amounts (1 g) of total RNA by the Superscript VILO cDNA
synthesis kit (Invitrogen, Carlsbad, CA) with random hexamers.
Quantitative real-time PCR analysis of transferrin receptor (TfR)-1,
whose expression is decreased with increasing intracellular iron
availability,35 heme oxygenase-1, induced by oxidative stress and
involved in neutralizing iron induced oxidative stress,36 MCP-1,
interleukin (IL)-6, tumor necrosis factor (TNF), tissue factor, and
CD36 mRNA levels, was performed by using the SYBR green
chemistry (Fluocycle, Euroclone, Siziano, Italy). Custom-designed
primers and reaction protocols are available on request. All the
reactions were performed in triplicate by the Opticon 2 analyzer
(Bio-Rad, Hercules, CA) in a 25-L final volume. Results were
normalized for 18S and -actin mRNA levels.
Evaluation of Basal Activation Status
of Monocytes
Basal activation status of monocytes was estimated based on the
percentage of CD69 positivity of CD14 cells at cytofluorimetric
analysis.37 The percentage of monocytes positive for CD69 or CD14
was quantified within 2 hours on a FACSscan flow cytometer
(Becton Dickinson). Aliquots of around 100 L of heparinised blood
were submitted to standard triple staining procedures with antiCD14
(Fl1), antiCD69 (Fl2) and antiCD45 (Fl3) monoclonal antibodies
(Becton Dickinson, San Jose`, CA).
Evaluation of Vascular Damage
Vascular damage was determined by measurement of the common
carotid arteries intima media thickness (CC-IMT) and plaque detec-
tion by echocolor–Doppler ultrasonography, as described
previously.27
Statistical Analysis
Data are shown as meansSD for normally distributed variables,
mean and interquartile range for nonnormally distributed variables
(log-transformed before analysis), and frequencies for categorical
variables. Data were compared by 2 and Wilcoxon tests, as
required, and variables were correlated by Spearman’s rho test. Gene
expression levels were compared by Wilcoxon signed-rank test for
paired samples and by Wilcoxon test for unpaired samples. Logistic
regression analysis was performed to adjust the association between
MCP-1 and the presence of plaques for confounding variables.
Values of P0.05 were considered statistically significant. All
analyses were performed with the JMP 6.0 statistical analysis
software (SAS institute, Cary, NJ).
Results
Risk-Associated HFE Genotypes Influence Iron
Handling, But Not Oxidative Stress, in
Differentiating Human Monocytes of Patients
With Hyperferritinemia
We first confirmed that treatment with iron salts increased
intracellular iron status in monocytes of patients with “nor-
mal” HFE genotype and evaluated whether HFE genotypes
predisposing to iron overload were associated with altered
iron metabolism in macrophages, by comparing the expres-
sion of TfR-1 mRNA, a sensitive marker of cellular iron
status, in differentiating monocytes isolated from patients
with hyperferritinemia related or not to the presence of HFE
genotypes associated with risk for disease. TfR-1 mRNA
transcripts are stabilized during iron deficiency by direct
binding of iron regulated proteins to the 3 untranslated
regions.35 Results are shown in Figure 1A. Treatment with
FAC determined a significant increase in intracellular iron
availability, as detected by a significantly higher decrease in
TfR-1 mRNA levels, in monocytes of patients with normal
HFE genotypes than in those of patients carrying HFE
genotypes that are associated with risk for iron overload
(P0.01), whereas TfR-1 levels were not significantly down-
regulated in monocytes of patients with HHC. In contrast,
FAC induced a similar upregulation of heme oxygenase-1
mRNA levels irrespective of the HFE genotype (Figure 1B).
These data suggest that monocytes of patients with HFE
genotypes associated with risk for iron overload had a partial
defect of iron retention reminiscent of that observed in classic
HHC,38 but not reduced oxidative stress.
Effect of Iron Treatment on the Expression and
Release of Atherogenic Factors in Human
Differentiating Monocytes is Influenced by
HFE Genotype
We next evaluated whether manipulation of iron status
modified the release of atherogenic mediators in monocytes
of patients with hyperferritinemia subdivided according to the
HFE genotype (Table 1). Treatment with FAC did not
significantly affect either TNF, tissue factor, or CD36
mRNA levels in monocytes of patients, irrespective of their
HFE genotype, and basal TNF, tissue factor, and CD36
mRNA levels were not significantly influenced by HFE
genotype (data not shown). In contrast, FAC treatment was
associated with a significant upregulation of MCP-1 and IL-6
mRNA levels in monocytes of patients with normal HFE
genotype compared to lack of treatment but not in monocytes
of patients with HFE genotypes associated with risk for iron
overload or with HHC (Figure 1C). Importantly, MCP-1 and
IL-6 mRNA levels in untreated cells were not significantly
influenced by the HFE genotype. Moreover, the percentage
of activation (CD69) of peripheral blood monocytes
(CD14) was not significantly different in patients with
hyperferritinemia subdivided according to the HFE genotype
(HFE normal: 10.415%, n8; risk HFE: 8.514%, n6;
C282Y/ HHC: 1315%, n8; healthy controls with nor-
mal ferritin and normal HFE: 7.29%, n6; PNS). These
and previous39 data suggest that altered HFE dysfunction
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does not influence basal activation status but is associated
with defective iron retention and a lack of proinflammatory
response to iron challenge in human monocytes.
Inflammatory Response to Iron Challenge in
Monocytes Correlates With Vascular Damage in
Patients With Hyperferritinemia
To evaluate the relationship between iron-dependent induc-
tion of cytokines and vascular damage, we analyzed whether
inducibility of MCP-1 and IL-6 in monocytes of patients with
hyperferritinemia (Table 1) was associated with the presence
of carotid plaques, an index of advanced vascular disease.
Results are shown in Figure 1D. Despite basal expression of
cytokines not being significantly different in untreated mono-
cytes (data not shown), both MCP-1 and IL-6 mRNA levels
were significantly more upregulated after iron challenge in
patients with (n10) than in those without (n16) carotid
plaques.
Effect of Iron and Hepcidin-25 Treatment on
Cytokines in Monocytes Derived From Healthy
Subjects With Normal Iron Metabolism
To assess whether MCP-1 and IL-6 induction after iron
challenge represented a physiological response to iron over-
load related to increased iron availability and hepcidin
upregulation in monocytes, we next evaluated the dose–
response relationship between FAC and hepcidin-25 treat-
ment and MCP-1 and IL-6 mRNA levels in monocytes of 7
healthy male subjects with normal iron metabolism and
absence of metabolic alterations. Data are presented in Figure
2A. Surprisingly, neither FAC nor hepcidin-25 induced a
significant upregulation of IL-6 mRNA levels in monocytes
of most of the healthy subjects (n6/7, 86%), whereas
increasing concentrations of both FAC and hepcidin-25
induced a progressive increase in MCP-1 mRNA levels.
However, we observed a very strong upregulation of IL-6 in
1 healthy control. The absence of MCP-1 upregulation after
H2O2 treatment indicates that the effect of iron is not
attributable to an unspecific induction by oxidative stress but
is likely a specific response to intracellular iron overload.
Next, we confirmed that increased MCP-1 transcription
induced by iron and/or hepcidin-25 treatment translated into
increased release of this chemokine in differentiating mono-
cytes, by measuring MCP-1 protein levels in cell supernatants
by ELISA (Figure 2B). Data indicate that the maximum
MCP-1 induction by FAC was already observed at 24 hours.
Serum Hepcidin-25, MCP-1, and Vascular Damage
in Patients With Metabolic Alterations
We finally evaluated the relationship among iron status,
hepcidin-25, and MCP-1 serum levels and vascular damage in
130 patients with NAFLD and MetS alterations.27
Hepcidin-25 levels were not correlated with available demo-
graphic and anthropometric features, the presence of diabetes,
dyslipidemia, hypertension, central obesity, the metabolic
syndrome, and with indices of inflammation or of altered
Figure 1. Effect of ferric ammonium citrate (FAC 150 mol/L) treatment on TfR-1 mRNA levels (A), heme oxygenase-1 (HO-1) mRNA
levels (B), and mRNA levels (C) of MCP-1 and IL-6 in monocytes of subjects with iron overload subdivided according to HFE genotype:
“normal,” “hepatic iron overload,” and hereditary hemochromatosis (HHC). *P	0.05 vs untreated cells; °P	0.05 vs normal HFE. D,
Association between the induction of MCP-1 and IL-6 mRNA after iron challenge in monocytes of subjects with iron overload and the
presence of carotid plaques. *P	0.05 vs absence of plaques.
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metabolism, but, as previously reported,22 with serum ferritin,
an index of body iron stores (Rho0.43; P	0.0001), and
with serum MCP-1 levels (Rho0.24; P0.005; Figure 3A).
In contrast, MCP-1 levels were not significantly correlated
with the other available demographic and anthropometric
features, and with indices of dysmetabolism and inflamma-
tion, including CRP levels (rho0.03, P0.78). Interest-
ingly, hepcidin levels were significantly correlated with
MCP-1 in patients without (n98, rho0.29, P0.003) but
not in those with diabetes (n32, rho0.12, P0.05),
suggesting that in the presence of diabetes, hyperglycemia
and its metabolic consequences plays the major role in
determining serum MCP-1 levels. However, serum MCP-1
levels were significantly higher in patients with (n44) than
in those without (n86) carotid plaques (121 pg/mL [inter-
quartile range, 78 to 193 pg/mL] versus 85 pg/mL [interquar-
tile range, 60 to 148 pg/mL]; P0.03; Figure 3B).
Patients with CRP levels above median value (0.1
mg/dL) had higher ferritin (542250 ng/mL versus
366260; P0.02) and a trend for higher hepcidin-25
(3.53.2 versus 2.51.7 nmol/L; P0.08) and IMT levels
(0.920.2 versus 0.800.2; P0.08) but not higher MCP-1
levels (11780 versus 11360 pg/mL; P0.7) or prevalence
of plaques (59 versus 63%; P0.7). These data suggest that
in this series of patients the association between iron indices
and MCP-1 levels, and the association between MCP-1 and
vascular damage, is independent of subclinical inflammation.
At multivariate analysis (Table 3), presence of carotid
plaques was significantly associated with ferritin (P0.013)
and MCP-1 (P0.05) serum levels, independently of classic
risk factors for atherosclerosis and of the presence of HFE
mutations.
Discussion
In this study, we evaluated the effect of the manipulation of
intracellular iron status by treatment with iron salts or the
hormone hepcidin on the release of atherogenic cytokines in
human differentiating monocytes of patients with mild iron
overload at high risk for cardiovascular disease.22,27 The
study was prompted by accumulating evidence indicating that
Figure 2. Dose–effect relationship
between FAC and hepcidin-25 concen-
trations in culture medium and the tran-
scriptional induction of MCP-1 and IL-6
in human differentiating monocytes from
healthy subjects (A) and the release of
MCP-1 in human differentiating mono-
cytes from healthy subjects (B). Mono-
cytes were incubated in the presence of
the aforementioned treatments for 24
hours. FAC indicates ferric ammonium
citrate. Results represent the meansSD
of 2 independent experiments. *P	0.05
vs untreated cells.
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iron overload may represent a risk factor for cardiovascular
diseases and that the mechanism may be mediated by iron
accumulation in arterial plaques macrophages, with conse-
quent induction of inflammation, release of proinflammatory
mediators, and transformation into foam cells.3,22,40 Indeed,
infiltration of the arterial wall by activated macrophages that
phagocytize oxidative stress–modified lipoproteins and secre-
tion of proinflammatory, fibrogenic, and extracellular matrix
remodeling mediators play a pivotal role in the pathogenesis
of the progression and complications of atherosclerotic
lesions.41
Our results indicate that treatment with iron salts determin-
ing increased intracellular iron increased the release of
MCP-1 and IL-6 independently of oxidative stress. Further-
more, the iron-dependent induction of MCP-1 and IL-6 was
associated with the severity of vascular damage in these
patients, suggesting that macrophage activation by iron may
be involved in the pathogenesis of vascular damage progres-
sion in these patients also in vivo.
IL-6 is a proinflammatory cytokine involved in the acute
phase response, whose serum levels correlate with cardiovas-
cular risk and have been linked to the inflammatory status
within atherosclerotic plaques.42 MCP-1 (also known as
CCL2), a chemokine involved in macrophage recruitment at
inflammation sites released by macrophages, but also by
smooth muscle cells and endothelial cells, plays a crucial role
in both the initiation and progression of atherosclerosis, and
MCP-1 serum levels reflect the atherosclerotic plaque burden.
Higher MCP-1 has also been reported to represent a negative
prognostic factor in acute coronary syndromes.43–45
A dose-dependent induction of MCP-1 transcription and
release in the supernatant induced by iron treatment was
confirmed in monocytes of healthy subjects with normal iron
parameters, suggesting that this represents a physiological
response to increased intracellular iron availability. These
data are in line with previous experimental evidence, suggest-
ing that iron may induce MCP-1 release by oxidative stress in
macrophages. Indeed, intravenous iron treatment induces
MCP-1 release by monocytes in mice and patients with
end-stage renal disease,46,47 whereas the iron chelator defer-
oxamine has recently been shown to decrease nuclear factor
B activation, MCP-1 release, macrophage infiltration in
vascular tissue, and atherosclerosis progression in ApoE/
mice.25 In contrast, possibly because of different cellular iron
handling caused by the absence of additional acquired and/or
genetic factors, we could not confirm an induction of IL-6 by
iron treatment in monocytes of most of the healthy subjects.
Importantly, we also showed that treatment with hepcidin,
which acts by blocking cellular iron export,15 mimicked the
effect of iron salts on MCP-1 release, as also reported in
preliminary form by others.48 In addition, we obtained evi-
dence that,38 monocytes of patients with HFE genotypes
predisposing to mild iron overload show reduced ability to
accumulate intracellular iron. Iron-induced upregulation of
MCP-1 and IL-6 was hampered in monocytes of patients
carrying these disease risk HFE genotypes, thus suggesting
that the lack of upregulation of proinflammatory mediators
may contribute to explain the lack of association between iron
overload and accelerated atherosclerosis in HHC patients and
explain the contradictory data on the effect of HFE mutations
on vascular damage.3,24 Consistently, despite the fact that iron
overload has been associated with increased serum MCP-1
levels, patients homozygous for the C282Y HFE mutation
had lower MCP-1 levels than those whose iron overload was
explained by other genetic/acquired factors and healthy con-
trols.49 Thus, iron-dependent release of MCP-1 by macro-
phages may be a mechanism involved in the pathogenesis of
accelerated atherosclerosis associated with iron overload and
Figure 3. A, Correlation between serum hepcidin-25 and MCP-1
levels in 130 patients with NAFLD and MetS abnormalities
(Rho0.24; P0.005). B, Comparison of serum MCP-1 levels
between patients with and without carotid plaques (P0.03).
Median values, interquartile range, and 10th/90th centiles are
shown.
Table 3. Independent Predictors of the Presence of Carotid
Plaques in One Hundred Thirty Patients With Nonalcoholic Fatty
Liver Disease and MetS Alterations as Evaluated by Logistic
Regression Analysis
Variable OR 95% CI P
Age, yr 1.12 1.06–1.18 	0.0001
Sex, male 1.98 0.96–4.54 0.08
BMI, kg/m2 0.75 0.65–0.84 	0.0001
Diabetes 3.37 1.22–11.9 0.028
Hypertension 1.94 1.10–3.56 0.025
Treated dyslipidemia 2.60 1.13–6.64 0.03
Active smoking 0.94 0.51–1.76 0.85
HFE mutations 0.90 0.53–1.52 0.70
MCP-1, pg/mL 1.01 1.00–1.02 0.05
Ferritin, ng/mL 1.01 1.00–1.02 0.013
BMI, body mass index; OR, odds ratio. All the independent variables
considered in the analysis are shown in the table.
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is consistent with the apparently paradoxical protective effect
of HFE mutations.
To assess whether this mechanism may be relevant in vivo,
we measured serum MCP-1 levels in a series of patients at
high risk for vascular disease because of MetS and fatty liver,
who typically display a high prevalence of altered iron
metabolism,22 with complete characterization of carotid ath-
erosclerosis and iron metabolism, including serum
hepcidin-25 evaluation, and HFE genotype determination. In
line with a possible induction of MCP-1 release by increased
iron in monocytes/macrophages, serum MCP-1 levels, whose
primary source is represented by activated macrophages,
were significantly correlated with hepcidin-25, and MCP-1
levels were an independent predictor of the presence of
carotid plaques, indicating an advanced atherosclerotic
process.
Thus, the emerging details of the physiology of hepcidin
suggest a resolution of the apparent paradox of an important
role of iron in atherogenesis in the absence of increased
plaque burden in HHC. Hepcidin, induced by iron and
inflammation, acts to block iron recycling from macrophages
by binding and causing internalization and degradation of
ferroportin, the sole cellular iron exporter. Low hepcidin
levels are observed in iron deficiency anemia and HHC, both
characterized by reduced macrophage iron stores. The failure
of vascular wall macrophages to retain iron in HHC may
therefore prevent the progression of atherosclerotic plaques.
In conclusion: (1) increased intracellular iron in human
differentiating monocytes, induced either by treatment with
iron salts or hepcin-25, induces MCP-1 transcription and
release; (2) the ability of iron treatment to induce MCP-1 is
correlated with the severity of vascular damage; and (3)
serum MCP-1 is associated with hepcidin-25 and vascular
damage in high-risk individuals with metabolic syndrome
alterations. These data support the hypothesis that MCP-1
release by intralesional monocytes/macrophages, which can
be iron-loaded because of intraplaque hemorrhage, systemic
iron overload, and local inflammation,3,17 is involved in the
pathogenesis of iron-induced atherosclerosis.
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